Identity
- Security key
- 24226
- Ticker
- ZYME
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2017-04-28
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ZYME
Detail
Enriched 2026-08-14 20:47
- Market cap
- $1,769,013,878.13
- Shares outstanding (class)
- 70,959,241
- Shares outstanding (weighted)
- 70,959,241
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 264
- Location
- MIDDLETOWN, DE
- Homepage
- https://www.zymeworks.com
- Description
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.